Timelines of translational science: From technology initiation to FDA approval

PLoS ONE

Volumn 12, Issue 5, 2017, Pages

  McNamee, Laura M ^a   Walsh, Michael Jay ^a   Ledley, Fred D ^a  

^a BENTLEY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; IVACAFTOR; RUXOLITINIB; SIMEPREVIR; SOFOSBUVIR; TESAMORELIN;

ARTICLE; DRUG APPROVAL; DRUG DESIGN; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; GENOMICS; GROWTH CURVE; HUMAN; MICROFLUIDICS; NONHUMAN; RNA INTERFERENCE; LEGISLATION AND JURISPRUDENCE; TRANSLATIONAL RESEARCH; UNITED STATES;

DRUG APPROVAL; HUMANS; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85019035241     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0177371     Document Type: Article

References (33)

1. Munos BH. Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery. 2009; 8:959-68. https://doi.org/10.1038/nrd2961 PMID: 19949401
2. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010; 87(3):272-7. Epub 2010/02/05. https://doi.org/10.1038/clpt.2009.295 PMID: 20130567
3. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nature reviews Drug discovery. 2012; 11(3):191-200. https://doi.org/10.1038/nrd3681 PMID: 22378269
4. Woodcock J. The PCAST Report on Pharmaceutical Innovation: Implications for the FDA. Clinical Pharmacology & Therapeutics. 2013; 94(3):297-300.
5. Sung NS, Crowley WF Jr, Genel M, Salber P, Sandy L, Sherwood LM, et al. Central challenges facing the national clinical research enterprise. Jama. 2003; 289(10):1278-87. PMID: 12633190
6. Woodcock J, Woosley R. The FDA Critical Path Initiative and Its Influence on New Drug Development&z.ast;. Annu Rev Med. 2008; 59:1-12. https://doi.org/10.1146/annurev.med.59.090506.155819 PMID: 18186700
7. Christensen CM. The innovator's dilemma: the revolutionary book that will change the way you do business: HarperBusiness Essentials New York, NY; 2003.
8. Christensen C. The innovator's dilemma: when new technologies cause great firms to fail: Harvard Business Review Press; 2013.
9. Foster RN. Innovation: The attacker's advantage: Summit Books New York; 1986.
10. McNamee LM, Ledley FD. Patterns of technological innovation in biotech. Nat Biotechnol. 2012; 30 (10):937-43. Epub 2012/10/12. https://doi.org/10.1038/nbt.2389 PMID: 23051809
11. Ledley F, McNamee L, Uzdil V, Morgan I. Why commercialization of gene therapy stalled; examining the life cycles of gene therapy technologies. Gene therapy. 2013.
12. McNamee L, Ledley F. Modeling timelines for translational science in cancer; the impact of technological maturation. in press at PLOS One.
13. Drews J. Drug discovery: a historical perspective. Science. 2000; 287(5460):1960-4. PMID: 10720314
14. Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science. 2000; 287(5460):1969-73. PMID: 10720316
15. Miklos GLG. The Human Cancer Genome Project-one more misstep in the war on cancer. Nature biotechnology. 2005; 23(5):535-7. https://doi.org/10.1038/nbt0505-535 PMID: 15877064
16. Kotz J. Phenotypic screening, take two. SciBX: Science-Business eXchange. 2012; 5(15).
17. Goldman M, Seigneuret N, Eichler H-G. The Innovative Medicines Initiative: an engine for regulatory science. Nature Reviews Drug Discovery. 2014.
18. Breckenridge A, Feldschreiber P, Gregor S, Raine J, Mulcahy L-A. Evolution of regulatory frameworks. Nature Reviews Drug Discovery. 2011; 10(1):3-4. https://doi.org/10.1038/nrd3348 PMID: 21193854
19. Swinney DC, Anthony J. How were new medicines discovered? Nature reviews Drug discovery. 2011; 10(7):507-19. https://doi.org/10.1038/nrd3480 PMID: 21701501
20. Bradley DW, McCaustland KA, Cook E, Schable CA, Ebert JW, Maynard JE. Posttransfusion non-A, non-B hepatitis in chimpanzees. Physicochemical evidence that the tubule-forming agent is a small, enveloped virus. Gastroenterology. 1985; 88(3):773-9. PMID: 2981754
21. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989; 244(4902):359-62. PMID: 2523562
22. Goodchild MC, Edwards J, Glenn KP, Grindey C, Harris R, Mackintosh P, et al. A search for linkage in cystic fibrosis. Journal of medical genetics. 1976; 13(6):417-9. PMID: 1018300
23. Drouin J-N, St-Pierre S, Regoli D. Receptors for bradykinin and kallidin. Canadian journal of physiology and pharmacology. 1979; 57(4):375-9. PMID: 455136
24. Müller E, Pecile A. Growth Hormone Releasing Factor of a Guinea-Pig Hypothalamic Extract Its Activity in Guinea Pig and Rat. Experimental Biology and Medicine. 1965; 119(4):1191-4.
25. Cockburn IM, Henderson RM. Absorptive capacity, coauthoring behavior, and the organization of research in drug discovery. The Journal of Industrial Economics. 1998; 46(2):157-82.
26. Eder J, Sedrani R, Wiesmann C. The discovery of first-in-class drugs: origins and evolution. Nature Reviews Drug Discovery. 2014; 13(8):577-87. https://doi.org/10.1038/nrd4336 PMID: 25033734
27. DiMasi JA, Paquette C. The economics of follow-on drug research and development. Pharmacoeconomics. 2004; 22(2):1-14.
28. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. Journal of health economics. 2016; 47:20-33. https://doi.org/10.1016/j.jhealeco.2016.01. 012 PMID: 26928437
29. Guedj I, Scharfstein D. Organizational scope and investment: Evidence from the drug development strategies and performance of biopharmaceutical firms. National Bureau of Economic Research, 2004.
30. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced drug delivery reviews. 2012; 64:4-17.
31. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014; 13 (6):419-31. https://doi.org/10.1038/nrd4309 PMID: 24833294
32. DiMasi JA. The value of improving the productivity of the drug development process. Pharmacoeconomics. 2002; 20(3):1-10.
33. Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clinical pharmacology & therapeutics. 2011; 89(2):183-8.